Clinical Trials

What is going on with Aduhelm? And why is the drug seen by some to be controversial?

A report from Clarivate has tipped 7 drugs for potential blockbuster status in 2022. Here’s what makes them stand out.

A 2000-participant study in Europe has examined how drugs – and combinations of drugs – can affect the microbiota in our gut.

Why the industry needs to finally wake up to the real-life benefits of real-world data.

An interview with Ken Gruber of Endevica Bio on his work producing a treatment for cachexia, a wasting condition common in late-stage cancer.

New ICH guideline revisions are imminent. Sue Batchelor of Cmed shares her thoughts on how sponsors and CROs can prepare themselves.

Joe Sinclair gives his view on how to be successful with oncolytic virotherapy.

Antibody drug conjugates are starting to transform cancer treatments, so let’s maintain the momentum.

Stating an intention to be ready to win in any biowarzone, the US military has commissioned Dynavax to develop a vaccine for the plague.

Biotech companies need good patient samples, but hospitals are not always obliging...